The top Japanese pharmaceutical companies are taking unprecedented steps to expand their US presence, leading US M&A trends to bolster pipelines, expand commercial presence and gain access to senior-level talent thru acquisitions/partnering. This trend of industry consolidation is expected to continue and represents an opportune time for smaller firms to repackage offerings and set an attractive valuation of their assets and expertise to make them a compelling investment. This session will offer advisory counsel and strategic insights into how top Japanese-based biopharmas approach deal-making activities in the US, and criteria they use to assess potential targets for acquisition/partnering.

• Provide counsel for smaller US firms to attract top Japan pharma companies as partners/investors
• Illustrate best practice approaches to valuation, negotiation, acquisition,and integration
• Share factors in assessing asset value (portfolio/platform) and pitfalls in packaging assets